Rua Life Sciences Share Discussion Threads

[bones] 13/1/2022 19:36

It just needs a good polish.

[cfb2] 13/1/2022 17:35

There has been steady selling over the past week and the price hasn't really moved. I have been forced to sell in 10k to 25k lumps.

Until RUA have provided insight into their latest road map for 510k submission and approval, your monkey may risk ending up with peanuts.

I'm assuming this latest failure added at least another 6 months on approval. RUA have increased their spending, revenue from patches and grafts is coming much later and their new manufacturing facilities will be sitting idle.

I was expecting a fund raise around the end of 2022 but now expect it within the next 6 months and I think it could be priced as low as 40p.

[the_real_mr_big] 13/1/2022 17:23

What surprises me is that £50k of RUA stock has been bought today, and share price hasn't moved. I thought our liquidity was lower.
A long wait to recovery I guess.

[the_real_mr_big] 13/1/2022 16:31

They say, a good way to win on stock market is to follow the monkey.

[redbraces] 13/1/2022 16:14

I think, Mr Optimistic, is trying to hit the upturn leg
of the big 'W' bottom, of the stock chart. I just hope
they are correct.

[the_real_mr_big] 13/1/2022 15:59

Somebody's optimistic at 68p...

[bones] 12/1/2022 11:07

Just to be sure, Langland!

[langland] 12/1/2022 10:33

LOL, bones. Though I'm not so sure. Whenever I get my car serviced, I always have the whole engine replaced.

[bones] 12/1/2022 09:51

If you need a valve replacement, you’re not going to need an entire heart. Two very different markets.

[buywell3] 12/1/2022 03:01

POST REMOVED

[cfb2] 11/1/2022 10:47

You must be referring to the pig heart transplant. They knocked out a number of genes to avoid rejection:


It's a win-win as they can recoup the cost of the operation from any truffles the patient finds.

[semper vigilans] 11/1/2022 10:34

I see the animal kingdom is trying to fight back in the heart transplant area.

[hedgehog11] 10/1/2022 20:22

Lol, lesson learned! I sure we'll receive a lot of information about the regulatory pathway and the cost well in advance of a rights issue.

[cfb2] 08/1/2022 16:20

I suggest you use Bill's confidence level as an early warning for a rights issue. The only reliable indicator to come from RUA.

[hedgehog11] 08/1/2022 15:05

Indeed, I weighted too much on RUA faith was so high! Perhaps I relied too much on company reports which were high in confidence and I may repeat the mistake based on Bills 'when not if' comments.
Hopefully by the time of the next RNS the share price is already reflecting the worst case scenario and the only way is up!

[hedgehog11] 05/1/2022 17:12

Apologies! thanks The_Real_Mr_Big!

[bones] 04/1/2022 18:40

Hedgehog11, the credit for the comments must go to The_Real_Mr_Big :)

[the_real_mr_big] 04/1/2022 09:49

Oh, and happy new year everyone.
Let's hope it's better than the 2021 fiasco.

[the_real_mr_big] 04/1/2022 09:49

Hedge - all imho - any funding will be to push the moneymaker tech into the market (at least in theory), so placings shouldn't hammer the share price no matter the % of dilution. IIs will happily eat this up and won't be dumping.

The "risk" of IP being sold off cheap means that you will get 3-4 bags from here instead of 6-8. So not really a risk at this share price level.

The only real risk is that RUA are selling snake oil and it will never ever work. Somehow I find it hard to believe that's the case. Everything else is just a matter of waiting.

But let's see what requirements the yanks come up with. Not long to wait, hopefully.

[hedgehog11] 02/1/2022 09:02

From an amateur investor, I don't subscribe on ADFN so can't post on the main thread. There doesn't seem to have been much discussion on how the next few years will be funded and the impact on share prices, can you throw some light on the risk below (ED 16th December), what are the possible outcomes for investors? "The deferral of RUA Vascular product revenues raises the spectre that bigger medical device companies,
and even its potential OEM partners for the products, might sense an opportunity. The pressures that a delay to revenues could bring, and the extent of the investment cost already spent on the product’s development, means they could attempt a licensing transaction at a fraction of our £74m valuation of RUA’s Vascular products, or acquire the whole portfolio today for about half the price of RUA’s market capitalisation a year ago" When you separate the R&D from the income generating business it looks cheap at around 10 x price to earnings, without factoring in the new products and R&D (and heart valve but I'm ignoring that for now). Shame so much of the R&D admin is lumped in with revenue generating activities.

[the_real_mr_big] 30/12/2021 18:34

Thanks pal.
Same thoughts here.